Humana Inc
Health Care
Humana Inc (HUM) Stock News
The latest HUM headlines and market coverage — 3 recent stories, updated throughout the day.
- Zacks Investment Research·
Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade
Humacyte, Inc. (HUMA) closed at $0.48, down 4.26% on a day when major market indices gained. The stock has declined 17.34% over the past month, underperforming the Medical sector. The company is expected to report an EPS of -$0.09 and revenue of $0.86 million in its upcoming earnings release. Humacyte currently holds a Zacks Rank of #4 (Sell), and its industry ranks in the bottom 28% of all industries.
- Zacks Investment Research·
Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note
Humacyte, Inc. (HUMA) stock declined 2.86% to $0.50, underperforming broader market gains. The stock has lost 13.23% over the past month. While the company expects EPS to improve 35.71% next quarter with revenue up 14.67%, full-year projections show earnings declining 53.85% despite revenue doubling. The stock holds a Zacks Rank #4 (Sell) rating, and its industry ranks in the bottom 27% of all sectors.
- Zacks Investment Research·
Can Qualcomm's Tie-Up With HUMAIN for AI PC Lift Its Shares?
Qualcomm has partnered with HUMAIN to launch the Horizon Ultra AI PC, powered by the Snapdragon X2 Elite platform featuring an 18-core Oryon CPU, Adreno GPU, and Hexagon NPU. The device enables AI workloads to run locally on enterprise PCs while maintaining cloud computing access. Qualcomm competes with NVIDIA and AMD in the growing AI PC market, though its stock has underperformed the industry over the past year.